FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Rallybio Corporation (RLYB)
Company Research
Source: Business Wire
- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women -- Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization - NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the presentation of results from a fetal and neonatal alloimmune thrombocytopenia (FNAIT) systematic literature review and meta-analysis at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, which is taking place in New Orleans, LA. The results of this research found that, in a pooled analysis of 198,062 pregnant women, 2.2% were HPA-1a negative and 32.3% of these women were also HLA-DRB3*01:01 positive and therefore at ~25-fold higher risk for alloimmunization. These rates are consistent with Rallybio’s current est
Show less
Read more
Impact Snapshot
Event Time:
RLYB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLYB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLYB alerts
High impacting Rallybio Corporation news events
Weekly update
A roundup of the hottest topics
RLYB
News
- Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual MeetingBusiness Wire
- Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough SummitBusiness Wire
- Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation HonoreeBusiness Wire
- Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and HaemostasisBusiness Wire
RLYB
Earnings
- 8/8/24 - Beat
RLYB
Sec Filings
- 9/17/24 - Form 8-K
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- RLYB's page on the SEC website